CLSD Clearside Biomedical Inc.

1.55
-0.15  -9%
Previous Close 1.7
Open 1.62
Price To Book 6.2
Market Cap 69,546,265
Shares 44,868,558
Volume 239,862
Short Ratio
Av. Daily Volume 850,421
Stock charts supplied by TradingView

NewsSee all news

  1. Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    - IND Submission for CLS-AX (axitinib injectable suspension) On Track for Mid-2020 -- Greater China Licensing Partnership and Updated NDA Resubmission Timeline for XIPERE™ (triamcinolone acetonide suprachoroidal

  2. Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer

    ALPHARETTA, Ga., March 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  3. Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea

    – Arctic Vision to Lead Expansion of Novel Approach to Treating Macular Edema Associated with Uveitis in Asia –– Clearside Eligible to Receive Upfront and Milestone Payments and Royalties on Product Sales –– Increasing

  4. Clearside Biomedical to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update on Wednesday, March 11, 2020

    ALPHARETTA, Ga., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  5. Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020

    ALPHARETTA, Ga., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released May 31, 2018 - mixed data. 12.3 ETDRS letters compared to 13.5 ETDRS letters in control arm.
Suprachoroidal CLS-TA - TYBEE
Diabetic Macular Edema (DME)
Phase 3 data released November 5, 2018 did not meet primary endpoint.
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
CRL received October 18, 2019. To resubmit by the end of August 2020.
XIPERE (Suprachoroidal CLS-TA)
Macular edema associated with non-infectious uveitis
Phase 1/2 one-year data from Cohorts 4 and 5 are expected in mid-2020. Two-year data from Cohorts 1-3 due 1Q 2020.
RGX-314
Wet age-related macular degeneration (wet AMD)
Phase 2 trial to commence 2H 2020 with interim data due 2021.
RGX-314
Diabetic retinopathy
Phase 1/2a trial to be initiated by the end of 2020.
CLS-AX
Wet age-related macular degeneration
Phase 1/2a trial to be initiated by the end of 2020.
CLS-AX
Wet age-related macular degeneration

Latest News

  1. Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    - IND Submission for CLS-AX (axitinib injectable suspension) On Track for Mid-2020 -- Greater China Licensing Partnership and Updated NDA Resubmission Timeline for XIPERE™ (triamcinolone acetonide suprachoroidal

  2. Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer

    ALPHARETTA, Ga., March 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  3. Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea

    – Arctic Vision to Lead Expansion of Novel Approach to Treating Macular Edema Associated with Uveitis in Asia –– Clearside Eligible to Receive Upfront and Milestone Payments and Royalties on Product Sales –– Increasing

  4. Clearside Biomedical to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update on Wednesday, March 11, 2020

    ALPHARETTA, Ga., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  5. Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020

    ALPHARETTA, Ga., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  6. Clearside Biomedical Pipeline Highlighted in Oral Presentations at the Annual Angiogenesis and Macula Society Meetings

    – Preclinical data presented on lead development asset, CLS-AX (axitinib injectable suspension) – – Suprachoroidal injection platform featured in multiple indications including wet AMD, uveitis, diabetic macular edema,

  7. Clearside Biomedical Announces Presentations to be Given at Angiogenesis and Macula Society Conferences

    ALPHARETTA, Ga., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  8. Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

    LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical,

  9. Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare Conference

    ALPHARETTA, Ga., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  10. Clearside Biomedical to Present at the Stifel 2019 Healthcare Conference

    ALPHARETTA, Ga., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  11. Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    – Recent Partnerships Support the Broad Applicability of Suprachoroidal Space Injection Platform to Potentially Treat Multiple Ocular Diseases – – Suprachoroidal Axitinib IND Submission Targeted for Mid-2020 –   –

  12. Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

    ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  13. Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

    ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  14. Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

    ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  15. Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

    ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  16. Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

    ALPHARETTA, Ga., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  17. Clearside Biomedical Featured at Multiple European Scientific Retinal Congresses

    ALPHARETTA, Ga., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  18. REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

    ROCKVILLE, Md. and ALPHARETTA, Ga., Sept. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based

  19. Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference

    ALPHARETTA, Ga., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  20. Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)

    ALPHARETTA, Ga., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people